Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Véronique Diéras, MD, on the optimal setting in which to receive a PARP inhibitor

Dr. Diéras, Senior Medical Oncologist, Head, Breast Cancer Group, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France, tells us about the setting in which a metastatic breast cancer patients should receive a PARP inhibitor

Tags: BreastESMO 2019

Published: 11 October 2019

Recent Videos: Breast

video

Véronique Diéras, MD, on the optimal setting in which to receive a PARP inhibitor

Dr. Diéras, Senior Medical Oncologist, Head, Breast Cancer Group, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France, tells us ...

video

Véronique Diéras, MD, on BRCA-positive metastatic breast cancer & PARP inhibitors

Dr. Diéras, Senior Medical Oncologist, Head, Breast Cancer Group, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France, on whether ...

video

George Sledge, MD, shares the most relevant findings from the MONARCH-2 trial

Dr. Sledge, Professor and Chief, Division of Oncology, Stanford Cancer Center, Stanford University School of Medicine, shares the most relevant ...

video

Dennis J. Slamon, MD, PhD, on the significance of the phase III MONALEESA-3 trial

Dr. Slamon, Professor and Chief of Hematology/Oncology, UCLA Department of Medicine, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women's ...

video

Véronique Diéras, MD, elaborates on the BROCADE 3 study presented at ESMO 2019

Dr. Diéras, Senior Medical Oncologist, Head, Breast Cancer Group, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France, discusses results ...

video

Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

Dr. Arun, Professor of Medicine, Breast Medical Oncology and Co-Director of Cancer Genetics, University of Texas, MD Anderson Cancer Center, ...

video

Banu Arun, MD, on PARP inhibitors in BRCA positive metastatic breast cancer

Dr. Arun, Professor of Medicine, Breast Medical Oncology and Co-Director of Cancer Genetics, University of Texas, MD Anderson Cancer Center, ...

video

Banu Arun, MD, regarding veliparib in breast cancer patients with BRCA mutations

Dr. Arun, Professor of Medicine, Breast Medical Oncology and Co-Director of Cancer Genetics, University of Texas, MD Anderson Cancer Center, ...

video

Joyce O’Shaughnessy, MD, elaborates on the MONALEESA-3 trial presented at ESMO 2019

Dr. O’Shaughnessy, Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center, shares results ...

video

Joyce O’Shaughnessy, MD, shares relevant findings from the MONARCH-2 trial

Dr. O’Shaughnessy, Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center, shares relevant ...

Related Videos

video-image

Véronique Diéras, MD, on BRCA-positive metastatic breast cancer & PARP inhibitors

video-image

George Sledge, MD, shares the most relevant findings from the MONARCH-2 trial

video-image

Dennis J. Slamon, MD, PhD, on the significance of the phase III MONALEESA-3 trial

video-image

Véronique Diéras, MD, elaborates on the BROCADE 3 study presented at ESMO 2019

video-image

Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

video-image

Banu Arun, MD, on PARP inhibitors in BRCA positive metastatic breast cancer

video-image

Banu Arun, MD, regarding veliparib in breast cancer patients with BRCA mutations

video-image

Joyce O’Shaughnessy, MD, elaborates on the MONALEESA-3 trial presented at ESMO 2019

video-image

Joyce O’Shaughnessy, MD, shares relevant findings from the MONARCH-2 trial

video-image

Joyce O’Shaughnessy, MD, on the role of CDK4/6 inhibitors in the management of TNBC

video-image

Joyce O’Shaughnessy, MD, shares results of the Impassion130 trial presented at ESMO 2019

video-image

Joyce O’Shaughnessy, MD, on differentiating CDK4/6 inhibitors

video-image

Sara M. Tolaney, MD, MPH, provides an overview of the results from the SOPHIA trial

video-image

Debu Tripathy, MD, elaborates on the SOPHIA trial in HER+ metastatic breast cancer

video-image

Debu Tripathy, MD, regarding CDK 4/6 inhibitors in the treatment of breast cancer

video-image

Debu Tripathy, MD, elaborates on outcomes from the ImPassion130 trial

video-image

Debu Tripathy, MD, shares the outcomes of the MONALEESA-7 in premenopausal metastatic breast cancer

video-image

Sara M. Tolaney, MD, MPH, on the efficacy & safety of combination eribulin + pembrolizumab

video-image

Debra Patt, MD, MPH, MBA, considers the role of CDK 4/6 inhibitors in advanced breast cancer

video-image

Sara M. Tolaney, MD, MPH, shares outcomes from the ImPassion130 study in TNBC

video-image

Debra Patt, MD, MPH, MBA, regarding the implications of the ImPassion130 trial in TNBC

video-image

Sara M. Tolaney, MD, MPH, shares outcomes from the MONALEESA-7 trial

video-image

Debra Patt, MD, MPH, MBA, on the important implications of the MONALEESA-7 trial

video-image

Neelima Denduluri, MD, elaborates on the SOPHIA trial data in HER+ metastatic breast cancer

video-image

Neelima Denduluri, MD, regarding the EMBRACA trial in HER2- metastatic breast cancer

video-image

Neelima Denduluri, MD, discusses outcomes from the ImPassion130 trial

video-image

Neelima Denduluri, MD, regarding the MONALEESA-7 trial in premenopausal metastatic breast cancer

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, comments on the TAILORx study from ASCO 2018

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, on the outcomes of the PERSEPHONE clinical trial

video-image

Neelima Denduluri, MD, on the outcomes of the SANDPIPER study presented at ASCO 2018

video-image

Neelima Denduluri, MD, looks back on the Short-HER trial from the 2017 ASCO Annual Meeting

video-image

Neelima Denduluri, MD, offers opinion on the PERSEPHONE trial in early HER2+ breast cancer

video-image

Neelima Denduluri, MD, tells us about the recent updates to breast cancer guidelines

video-image

Neelima Denduluri, MD, comments on the role of CDK4/6 inhibitors

video-image

Neelima Denduluri, MD, regarding the implications of the TAILORx study from ASCO 2018

video-image

Neelima Denduluri, MD, speculates on the implications of taselisib data at ASCO 2018

video-image

Neelima Denduluri, MD, on the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Neelima Denduluri, MD, considers whether the results of TAILORx are practice-changing

video-image

Julie Gralow, MD, speculates on taselisib as a standard of care based on the results of SANDPIPER

video-image

Julie Gralow, MD, tells us about the SANDPIPER proof of concept trial presented at ACSO 2018

video-image

Julie Gralow, MD, comments on the practice-changing implications of the TAILORx study

video-image

Julie Gralow, MD, discusses outcomes from the TAILORx study presented at ASCO 2018

video-image

Julie Gralow, MD, regarding the reduction in cardiac events in the PERSEPHONE study

video-image

Julie Gralow, MD, reflects on the PERSEPHONE trial from the 2018 ASCO Annual Meeting

video-image

Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancer

video-image

Julie Gralow, MD, speaks to the significance of the MONALEESA-3 study

video-image

Julie Gralow, MD, elaborates on how to differentiate CDK4/6 inhibitors

video-image

Douglas W. Blayney, MD, discusses the biggest takeaway regarding breast cancer here at ASCO 2018

video-image

Douglas W. Blayney, MD, on if the results of the TAILORx study practice changing

video-image

Douglas W. Blayney, MD, discusses the implications of the TAILORx study

video-image

Douglas W. Blayney, MD, discusses the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Douglas W. Blayney, MD, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably

video-image

Sara M. Tolaney, MD, MPH on whether CDK4/6 inhibitors can be used interchangeably

video-image

Sara M. Tolaney, MD, MPH tells us about the outcomes of the MONARCH 2 study

video-image

Sara M. Tolaney, MD, MPH discusses the practice changing outcomes of the TAILORx study

video-image

Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 study

video-image

Sara M. Tolaney, MD, MPH, on whether the results of the TAILORx study are “practice changing”

video-image

Debu Tripathy, MD, on immunotherapies being studied for treatment of metastatic breast cancer

video-image

Debu Tripathy, MD, shares his impressions of the MONALEESA-2 study

video-image

Debu Tripathy, MD, regarding the results of the MONARCH-2 study

video-image

Debu Tripathy, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

video-image

Mohammad Jahanzeb, MD, FACP, on immunotherapy and treatment of metastatic breast cancer

video-image

Mohammad Jahanzeb, MD, FACP, discusses the results of the MONARCH-2 study presented at ASCO

video-image

Mohammad Jahanzeb, MD, FACP, on the impact of the APHINITY study presented at ASCO

video-image

Neelima Denduluri, MD, discusses exciting new approaches to treating breast cancer

video-image

Neelima Denduluri, MD, describes how CDK 4/6 inhibitors impact breast cancer treatment

video-image

Neelima Denduluri, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer

video-image

Neelima Denduluri, MD, discusses the results of the MONARCH-2 study presented at ASCO

video-image

Julie Gralow, MD, shares perspective on the evolving development immunotherapies in breast cancer

video-image

Lee Schwartzberg, MD, interprets the results of the PALOMA-2 study presented at ASCO 2016

video-image

Lee Schwartzberg, MD, on how liquid biopsies can be used for breast cancer treatment strategies

video-image

Julie Gralow, MD, shares her thoughts on the topic of liquid biopsy in breast cancer.

video-image

Julie Gralow, MD, shares her thoughts on new drugs in development for breast cancer.

video-image

Julie Gralow, MD, on the KRISTINE study

video-image

Julie Gralow, MD, discusses the Monarch 1 study

video-image

Julie Gralow, MD, discusses the outcomes of the PALOMA-2 study presented at ASCO 2016

video-image

Jasgit Sachdev, MD, on new drugs for treating patients w/ triple negative breast cancer.

video-image

Jasgit Sachdev, MD, on liquid biopsy as a promising technology for breast cancer treatment

video-image

Jasgit Sachdev, MD, discusses the PALOMA-2 randomized study

video-image

Mohammad Jahanzeb, MD, FACP on the role of CDK inhibitors and their evolving role in breast cancer

video-image

Mohammad Jahanzeb, MD, FACP comments on rising drug costs relative to more effective therapies

video-image

Mohammad Jahanzeb, MD, FACP talks about impact of CDK4/6 inhibition added to letrozole

video-image

Debu Tripathy, MD on the evidence of palbociclib (Ibrance) efficacy in the PALOMA-2 trial

video-image

Debu Tripathy, MD discusses the PALOMA-2 trial outcomes in ER+/HER2- advanced breast cancer

video-image

Debu Tripathy, MD, on the use of hormonal therapy in the PALOMA-2 clinical study

video-image

Debu Tripathy, MD provides update on breast cancer treatment algorithms impacted by PD-L1

video-image

Debu Tripathy, MD explains how liquid biopsy figures into breast cancer treatment

video-image

Debu Tripathy, MD regarding the MONARCH 1 (abemaciclib) study

video-image

Debu Tripathy, MD on the importance of cdk4/6 for future breast cancer treatments

video-image

Lee S. Schwartzberg, MD, FACP on exciting studies for breast cancer investigational agents

video-image

Lee S. Schwartzberg, MD, FACP discussing Paloma 2 study results from ASCO 2016

video-image

Debu Tripathy, MD, provides perspective on the treatment of HER2+ breast cancer patients

video-image

Shirish M. Gadgeel MBBS, comments on significant studies in ALK+ NSCLC from ESMO 2019

video-image

Robert L. Coleman, MD, FACOG, FACS, on takeaways from the ovarian plenary session at ESMO '19

video-image

Amer Zeidan, MBBS, comments on the influx of investigational oral agents in myeloid malignancies

video-image

Arndt Vogel, MD, elaborates on some of the key takeaways from the GO30140 trial

video-image

George Sledge, MD, explains how MONARCH-2 may impact the current standard of care

video-image

Dennis J. Slamon, MD, PhD, discusses implications from the MONALEESA-3 trial

video-image

Nader Sanai, MD, offers perspective on the challenges in treating glioblastoma

video-image

Christian Rolfo, MD, PhD, MBA, on the role of liquid biopsy in the treatment of lung cancer

video-image

Ulrik Lassen, MD, PhD, on whether testing for TRK fusion is easy and reliable

video-image

Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRC

video-image

Stefan Kasper, MD, provides updates on the BEACON trial in BRAF-mutant CRC

video-image

Shirish M. Gadgeel MBBS, speculates on the future of RET-altered NSCLC

video-image

Robert L. Coleman, MD, FACOG, FACS, on the VELIA, PAOLA-1 and PRIMA studies

video-image

Amer Zeidan, MBBS, on his study investigating onvansertib + cytarabine or decitabine in AML

video-image

Arndt Vogel, MD, elaborates on the results of the CheckMate-459 study in HCC

video-image

Brian Van Tine, MD, shares some of the top studies in sarcoma presented at ESMO 2019

video-image

Deborah Shrag, MD, MPH, on which biomarkers are important in the diagnosis & management of CRC

video-image

Nader Sanai, MD, shares details from the most promising studies in glioma presented at ESMO 2019

video-image

Christian Rolfo, MD, PhD, MBA, on the development of RET-Fusion in NSCLC

video-image

Ulrik Lassen, MD, PhD, discusses the incidence of TRK fusion in various tumor types

video-image

Scott Kopetz, MD, shares updates from the BEACON trial in BRAF-mutant colorectal cancer

video-image

Stefan Kasper, MD, explains the dosing and administration schedule of cetuximab

video-image

Shirish M. Gadgeel MBBS, regarding the most exciting data in lung cancer from ESMO 2019

video-image

Robert L. Coleman, MD, FACOG, FACS, on how veliparib factors into ovarian cancer treatment

video-image

Brian Van Tine, MD, considers the role of real-world outcomes in the treatment of sarcoma

video-image

Arndt Vogel, MD, offers his opinion on pemigatinib in the management of cholangiocarcinoma

video-image

Jason J. Luke, MD, FACP, on the role of CAR-Ts in the treatment of solid tumors

video-image

David Gershenson, MD, on considerations for maintenance therapy in ovarian cancer

video-image

David Gershenson, MD, tells us what's new in the treatment of rare epithelial cancers

video-image

David Gershenson, MD, elaborates on the role of MEK inhibitor trametinib in LGSC

video-image

Arndt Vogel, MD, shares his impression of the FIGHT-202 trial in cholangiocarcinoma

video-image

Ahmed Kaseb, MD, considers the effectiveness of bevacizumab + atezolizumab in HCC

video-image

Brian Van Tine, MD, discusses the design of the SPEARHEAD-1 trial

video-image

Jason J. Luke, MD, FACP, on the most compelling data in metastatic melanoma from ESMO 2019

video-image

Ahmed Kaseb, MD, elaborates on the phase 1b study investigating atezolizumab + bevacizumab in HCC

video-image

Christopher J. Hoimes, MD, considers the role of I-O in perioperative muscle-invasive bladder cancer

video-image

Brian Van Tine, MD, on the most promising investigational agents in advanced sarcoma

video-image

Jason J. Luke, MD, FACP, on how data from ESMO 2019 may impact the treatment of melanoma

video-image

Ahmed Kaseb, MD, offers opinion on nivolumab + ipilimumab in resectable HCC

video-image

Christopher J. Hoimes, MD, comments on the design and outcomes of KEYNOTE-866

video-image

Christopher J. Hoimes, MD, regarding the EV-103 study presented at ESMO 2019

video-image

Geoffrey Oxnard, MD, on the effectiveness of lorlatinib as a frontline agent in ALK+ NSCLC

video-image

Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC

video-image

Suresh Ramalingam, MD, provides perspective on the PD-L1 and TMB biomarkers in lung cancer

video-image

David Spigel, MD, on how results from the FLAURA study impact treatment selection in lung cancer

video-image

Suresh Ramalingam, MD, offers opinion on optimal sequencing of immunotherapy in NSCLC

video-image

Michael J. Birrer, MD, PhD, considers the benefits of various PARP inhibitors in ovarian cancer

video-image

David Spigel, MD, tells us about the results of CheckMate-227 presented at ESMO 2019

video-image

Suresh Ramalingam, MD, on how the FLAURA trial may impact care for EGFR-mutated NSCLC

video-image

Marwan Fakih, MD, considers implications from the AMG 510 trial

video-image

Michael J. Birrer, MD, PhD, regarding BRCA status in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, on the role of maintenance therapy in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, elaborates on the outcomes from the FORWARD I study

video-image

Michael Birrer, MD, on the key takeaways from the ovarian plenary session in ovarian cancer at ESMO 2019

video-image

David Spigel, MD, on the use of genomic markers like TMB to guide 1st NSCLC treatment

video-image

Geoffrey Oxnard, MD, on the FLAURA study impacting treatment selection in EGFR mutant lung cancer

video-image

Marwan Fakih, MD, on whether MSI-high is a “must-have” biomarker for CRC patients

video-image

Suresh Ramalingam, MD, discusses the results of CheckMate 227 in advanced NSCLC patients

video-image

Nader Sanai, MD, on the role of ribociclib in the management of gliomas

video-image

Suresh Ramalingam, MD, FASCO, shares results from the FLAURA trial presented at ESMO 2019

video-image

Marwan Fakih, MD, discusses the Phase 1 trial evaluating AMG 510 in CRC and NSCLC